Abstract:Objectives Tissue inhibitor of metalloproteinases-1 (TIMP-1) is considered to play a key role in the development of pulmonary arterial hypertension (PAH). However, the molecular regulatory mechanisms of TIMP-1 in the pulmonary arteries were not very clear, especially in the human pulmonary arterial smooth muscle cells (HPASMCs). This study try to investigate the signalling pathway involved in the regulation of TIMP-1 in HPASMCs stimulated with transforming growth factor (TGF)-β1. Methods Cultured HPASMCs were incubated with different concentrations of TGF-β1 (0, 2.5, 5, 10, 20 or 40 ng/ml) for 24 h, or with 10 ng/ml TGF-β1 for different time (1, 4, 8, 12, 24 or 48 h). Western blot and real-time PCR were employed to detect the protein and mRNA expression of TIMP-1 in HPASMCs, and enzyme-linked immuno sorbent assay (ELISA) was used to detect the secretion of TIMP-1 in the culture medium. Then, the activities of three mitogen-activated protein kinases (MAPK), including extracellular signal-regulated kinase 1/2 (ERK1/2), p38 and c-Jun NH2-terminal kinase (JNK), were respectively inhibited with their specific inhibitors, U0126, SB202190 and SP600125. The protein and mRNA of TIMP-1 were also detected to help distinguishing that which kinase was involved in the regulation of TIMP-1 in HPASMCs induced by TGF-β1. Besides this, mithramycin, a specific inhibitor of Sp1 transcription factor, and curcumin, a specific inhibitor of activator protein-1 (AP-1), were used to block the DNA-binding activity of Sp1 or AP-1 respectively. And electrophoretic mobility shift assay (EMSA), Western blot and real-time PCR were carried out to help confirming that which transcription factor was involved in the regulation of TIMP-1 in HPASMCs. Results Western blot, real-time PCR and ELISA analysis showed that TGF-β1 could time- and dose-dependently enhance the expression and secretion of TIMP-1. Furthermore, TGF-β1 could phosphorylate two kinases of MAPK, ERK1/2 and p38, but not JNK, and the phosphorylation of p38 was weaker compared with ERK1/2. Of these kinases, only the inhibition of ERK 1/2 by U0126 effectively blocked the TGF-β1-induced expression of TIMP-1. Mithramycin also significantly reduced the expression of TIMP-1 via blocking the DNA-binding activity of Sp1. However, the inhibition of AP-1 by curcumin couldn't achieve this result. Additionally, the results of EMSA showed that TGF-β1 could up-regulate the DNA-binding activity of Sp1, and that U0126 and mithramycin could effectively suppressed this activation in a dose-dependent manner. Conclusions TGF-β1 could time- and dose-dependently stimulate the expression and secretion of TIMP-1 in HPASMCs, and ERK1/2 and Sp1 signalling pathways might be involved in these activities.

Transforming Growth Factor Β1 (Tgf-Β1) Appears to Promote Coronary Artery Disease by Upregulating Sphingosine Kinase 1 (SPHK1) and Further Upregulating Its Downstream TIMP-1

The Increased TIGIT-Expressing CD3+CD56+ Cells Are Associated with Coronary Artery Disease and Its Inflammatory Environment.

ACTIVATION OF ERK 1/2 AND SP1 MAY CONTRIBUTE TO THE EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 INDUCED BY TRANSFORMING GROWTH FACTOR-β1 IN HUMAN PULMONARY ARTERIAL SMOOTH MUSCLE CELLS

Transforming Growth Factor Beta (Tgf-Β) Mediates Cardiac Fibrosis and Induces Diabetic Cardiomyopathy

Serum TGF-β1 and SMAD3 Levels Are Closely Associated with Coronary Artery Disease

Regulation of TGF‑β1 on PI3KC3 and Its Role in Hypertension‑induced Vascular Injuries

Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1–Endothelin-1 Signal Pathway

Association of Transforming Growth Factor-beta1 with Intimal Thickening and Proliferation of Smooth Muscle Cell in Human Coronary Artery

TGF-β1 and TIMP1 Double Directional Raav Targeted by UTMD in Atherosclerotic Vulnerable Plaque

Apolipoprotein A1 Inhibits the TGF-β1-Induced Endothelial-to-Mesenchymal Transition of Human Coronary Artery Endothelial Cells

Transforming Growth Factor Β and Its Role in Heart Disease.

Circ_0006251 mediates the proliferation and apoptosis of vascular smooth muscle cells in CAD via enhancing TET3 and PPM1B expression

Sphk1/S1p Mediates Tgf-Beta 1-Induced Proliferation Of Pulmonary Artery Smooth Muscle Cells And Its Potential Mechanisms

Abnormal Expression of TGFBR2, EGF, LRP10, and IQGAP1 is Involved in the Pathogenesis of Coronary Artery Disease.

Influences of transforming growth factor-β1 on scavenger receptor class A and class B (CD36) in THP-1 derived macrophages

Direct Transfer Of Transforming Growth-Factor-Beta-1 Gene Into Arteries Stimulates Fibrocellular Hyperplasia

Transforming growth factor-β1 inhibits interleukin-1β-induced expression of inflammatory genes and Cathepsin S activity in human vascular smooth muscle cells

Effect of transforming growth factor-β1 on human aortic vascular smooth muscle cell phenotype switch and mechanism

C1q/TNF-related Protein-1: an Adipokine Marking and Promoting Atherosclerosis

PDE1A is involved in TGF-β1-induced-collagen Type 1 Expression in Vascular Adventitial Fibroblasts

Transforming growth factor beta signaling via ALK1 and ALK5 regulates distinct functional pathways in vein graft intimal hyperplasia